Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
02 September 2024 - 9:00PM
Lucinda
Crabtree joins Oxford Biomedica as Chief Financial Officer
today
Oxford, UK – 2 September
2024: Oxford Biomedica plc (LSE:OXB) (“Oxford
Biomedica”, "OXB" or “the Company”), a quality and innovation-led
cell and gene therapy CDMO, announces that Lucinda (Lucy) Crabtree
Ph.D. has today joined Oxford Biomedica as Chief Financial Officer
(CFO) and board member. Lucinda’s appointment was previously
announced on 17 July 2024.
Lucinda Crabtree was previously at MorphoSys AG
where she served as CFO, leading a finance team across the US and
Germany until the company’s acquisition by Novartis. Previously,
she was CFO at Autolus Therapeutics, a Nasdaq listed clinical stage
biopharmaceutical company. Lucinda also brings extensive experience
from the investment and banking sectors, having held roles at
institutions including Woodford Investment Management, Goldman
Sachs, and Jefferies.
Dr. Frank Mathias, Chief Executive
Officer of Oxford Biomedica, commented: "We are thrilled
that Lucy has joined Oxford Biomedica as our new CFO and Board
member today. Lucy brings a wealth of experience from her roles as
a CFO and time as a healthcare investor and equity research
analyst. Her experience will be invaluable as we grow our
international position as a leading cell and gene therapy
CDMO.”
Lucinda Crabtree, Chief Financial
Officer of Oxford Biomedica said: “I am excited to be
joining Oxford Biomedica as CFO today. I firmly believe in the
Company’s growth strategy and am looking forward to working with
the Board and the rest of the leadership team. Together, I’m
confident we will fulfil our mission of enabling our growing client
base to deliver life-changing therapies to patients."
-Ends-
Enquiries:
Oxford Biomedica
plc:
Sophia Bolhassan, Head of Investor
Relations – T: +44 (0) 1865 509 737 / E: ir@oxb.com
ICR Consilium:T: +44
(0)20 3709 5700 / E: oxfordbiomedica@icrhealthcare.com
Mary-Jane Elliott / Angela Gray / Davide
Salvi
About Oxford Biomedica
Oxford Biomedica (LSE:
OXB) is a quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a
mission to enable its clients to deliver life changing therapies to
patients around the world.
One of the original
pioneers in cell and gene therapy, OXB has more than 25 years of
experience in viral vectors; the driving force behind the majority
of cell and gene therapies. OXB collaborates with some of the
world's most innovative pharmaceutical and biotechnology companies,
providing viral vector development and manufacturing expertise in
lentivirus, adeno-associated virus (AAV), adenovirus, and other
viral vector types. Oxford Biomedica's world-class capabilities
span from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems,
analytical methods and depth of regulatory expertise.
OXB offers a vast
number of unique technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the
TetravectaTM system), dual plasmid system for AAV production,
suspension and perfusion process using process enhancers and stable
producer and packaging cell lines.
Oxford Biomedica, a
FTSE4Good constituent, is headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK,
Lyon and Strasbourg, France, and near Boston, MA, US. Learn more
at www.oxb.com, and follow us
on LinkedIn and YouTube.
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Dec 2023 to Dec 2024
